KRS Global Biotechnology, Inc, Boca Raton, FL

Is KRS Global Biotechnology, Inc registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels its entry 503B, with FDA’s note “Out of business”.

Does KRS Global Biotechnology, Inc hold a Florida pharmacy license?

The Florida Board of Pharmacy lists 2 licenses for this name and city, as of Nov 15, 2026: PH23506 for KRS GLOBAL BIOTECHNOLOGY, INC, BOCA RATON, status Closed and PH28942 for KRS GLOBAL BIOTECHNOLOGY, INC., BOCA RATON, status Closed. The Colorado State Board of Pharmacy also lists nonresident license OSP 5777 for KRS Global Biotechnology, Inc, Boca Raton, FL, status Voluntary Surrender, as of Nov 15, 2026. The Illinois Department of Financial and Professional Regulation also lists nonresident license 054016707 for KRS GLOBAL BIOTECHNOLOGY, BOCA RATON, FL, status CLOSED, as of Nov 13, 2026. The Connecticut Department of Consumer Protection also lists nonresident license PCN.0002093 for KRS GLOBAL BIOTECHNOLOGY (dba GBTR), BOCA RATON, FL, status INACTIVE, as of Nov 15, 2026. The Delaware Division of Professional Regulation also lists nonresident license A9-0000861 for KRS Global Biotechnology, Inc., BOCA RATON, FL, status Closed, license A9-0002490 for KRS Global Biotechnology, Inc., BOCA RATON, FL, status Closed, license AA-0000028 for KRS Global Biotechnology, Inc., BOCA RATON, FL, status Closed and license AA-0000071 for KRS Global Biotechnology, Inc., BOCA RATON, FL, status Closed, as of Nov 10, 2026.

Has KRS Global Biotechnology, Inc had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 FMD-145 letter (Jun 13, 2019) for KRS Global Biotechnology, Inc. State board actions: record found. The Florida Board of Pharmacy’s enforcement list for pharmacy permits lists 4 actions: “Obligation(s) Satisfied” dated Sep 16, 2021, case 201934189 on license PH23506, “Obligation(s) Satisfied” dated Sep 16, 2021, case 201934186 on license PH28942 and “Administrative Complaint Filed” dated Oct 1, 2020, case 201934189 on license PH23506, and 1 more listed below. The California State Board of Pharmacy’s posted disciplinary decisions on facility licenses also lists 2 actions: “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Apr 3, 2019, case AC 6315 on nonresident license NRP 1007 and “Through a disciplinary action of the Board, the license is voluntarily surrendered” dated Apr 3, 2019, case AC 6315 on nonresident license NSC 99554. The Colorado State Board of Pharmacy’s license dataset also lists 6 actions: “CLS Voluntary Surrender/Relinquishment” dated Mar 25, 2020, case 2020-588 on nonresident license OSP 5777, “ITRM Summary Suspension” dated Feb 6, 2020, case 2020-588 on nonresident license OSP 5777 and “CLS Stipulation” dated Aug 23, 2010, case 2010-2043 on nonresident license OSP 5777, and more listed below.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
KRS Global Biotechnology, Inc
Location
Boca Raton, FL
Type as FDA labels it
503B
FDA’s note
Out of business
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
1
Warning letters on FDA’s actions page
0
Latest action on that page
Sep 12, 2019
FDA Data Dashboard inspections
4 inspections: 2 OAI, 2 VAI; 3 published Form 483s
Form 483 text on this page
1 Form 483, 14 observations
State board records
License found: PH23506, Closed; PH28942, Closed

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as KRS Global Biotechnology, Inc, a 503B facility, with 3 dated actions.

Document
Sep 12, 2019Recall noticeFirm Recall Announcement : KRS Global Biotechnology, Inc. Issues Voluntary Nationwide Recall of All Human and Animal Sterile Drug Products Due to Lack of Assurance of Sterility (09/12/2019)FDA copy (archived)
Aug 20, 2019Amended Form 483Amended 483 Issued 08/20/2019fda.gov
Jun 13, 2019FMD-145 letterFMD-145 Letter Issued 06/13/2019Not linked by FDA

A Form 483 lists investigator observations, not a final FDA determination. An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists KRS Global Biotechnology, Inc, Boca Raton, FL (FEI number 3006412304), matched to this page by exact name, city and state. It lists 4 inspections: 2 OAI, 2 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Aug 14, 2019Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30064123041099535
Oct 23, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30064123041029456
Aug 31, 2016Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)3006412304986013
Mar 17, 2014Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3006412304870308

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483 for this site has 14 numbered observations in all. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Jul 30, 2019 to Aug 14, 2019: 14 observations

Firm on the cover
KRS Global Biotechnology, Inc, 791 Park of Commerce Blvd Ste 600, Boca Raton, FL 33487-3633
FEI number
3006412304
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
555 Winderley Place, Suite 200 Maitland, FL 32751
Matched to this page by
FEI number on the cover; linked from actions page
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

The quality control unit lacks the responsibility and authority to approve and reject all components, drug product containers, in process materials and drug products.

Specifically,

A. Your Quality Unit released and distributed <Redacted B4> batches of sterile drug products that failed sterility testing. oos 1910 documents the sterility failure for L-ASPARAGINASE, COMPOUNDED STERILE 10,000 IUNIAL LYOPHILIZED, Lot 07022018@1 and OOS 2037 documents the sterility failure for NOREPINEPHRINE 8MG ADDED TO 5% DEXTROSE 250 ML BAG (PF), Lot 03122019@10. <Redacted B4> vials of L-ASPARAGINASE, COMPOUNDED STERILE 10,000 IUNIAL LYOPHILIZED, Lot 07022018@1 and <Redacted B4> bags of NOREPINEPHRINE 8MG ADDED TO 5% DEXTROSE 250 ML BAG (PF), Lot 03122019@10 were released and distributed.

B. Your Quality Unit released <Redacted B4> sterile drug batches when Too Numerous to Count (TNTC) bacteria were identified from <Redacted B4> in your firm's <Redacted B4> system on 04/25/19. Port <Redacted B4> and Port <Redacted B4> which are part of a <Redacted B4>, are used in the production of sterile drug products. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established.

Specifically,

A. Smoke studies perfo1med 07/12/1 9 are deficient for the following reasons:

Smoke studies do not demonstrate operational processes which includes IV bags, vials, and syringes inside LAFWs, BSC hoods, and the <Redacted B4> located in room <Redacted B4> •

AM ENDMENT 1

Th e dynamic smoke study conducted in ISO 5 Clean Room <Redacted B4> with the <Redacted B4> , does not demonstrate laminar airflow. Turbulent airflow 1s documented.

The smoke studies demonstrating the transfer of <Redacted B4> to the <Redacted B4> are deficient as they do not show the flow of smoke over the vials.

B. <Redacted B4> are placed under non-HEPA filtered air during prior to transfer to the <Redacted B4> in Room <Redacted B4> J

Observation 3

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

Specifically,

A. Your firm failed to determine a root cause, perform an assessment of additional batches that may be affected, and take preventative and corrective actions for out-of-specifications (00S) found during environmental monitoring (EM) from 07/16/18 to 05/22/19. The following 00S reports document the EM excursions: 1908, 1911, 1919, 1920, 1937, 1938, 1942, 1945, 1949, 1955, 1960, 1963, 1965, 1966, 1968, 1969, 1972, 1979, 1985, 1986, 1989, 1990, 1995, 2003,2005, 2006,2007,2008,2014,2015, 2019, 2033, 2057, 2059, 2075. Organisms included, but were not limited to the following: Nectiia sp., Eurotium sp., Candida albicans, Chiysonillia sp., Rhizopus sp., and Bacillus sp.

B. Your firm failed to determine a root cause, perform an assessment of additional batches that may be affected, and take preventative and corrective actions for the following out-of-specifications (00S) found during sterility testing from 07/02/18 to 05/13/19. ...

Read the full 483 (PDF on fda.gov)

Observation 4

Aseptic processing areas are deficient regarding air supply that is filtered through high-efficiency particulate air filters under positive pressure.

Specifically,

1 41 A. I SO 5 Clean Room <Redacted B4> and ISO 5 Clean Room <Redacted B4> have ceiling tiles and light fixtures at are Non-HEPA filtered. For example, non-HEPA tiles are located above the <Redacted B4> in ISO 5 Clean Room <Redacted B4> and non-HEPA tiles located immediately next to the <Redacted B4> in ISO 5 Clean Room.

B. The July 2019 Clean Room Inspection Report states room certifications were conducted "at-rest." Clean Rooms <Redacted B4> contain automated equipment.

C. The door remains open from the non-classified prep area to ISO 8 Prep Room <Redacted B4> The room certification was performed with the door closed.

AM ENDMENT 1

E. The <Redacted B4> hood certifications does not state the certification was performed under dynamic conditions.

Observation 5

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

A. HEP A filters located in Clean Rooms <Redacted B4> and in the ISO 5 LAFW and BSC hoods are sprayed directly with cleaning agents during cleaning procedures. In addition, surfaces other than the hoods and tables, are not wiped after being sprayed.

B. On 08/01/19, I observed an operator use one sterile wipe to clean an ISO 5 LAFW, then wipe down a stainless-steel table (upper and lower shelves), and then clean another ISO 5 hood.

C. Your firm lacks antimicrobial effectiveness testing of cleaning agents used in the ISO 5 areas.

D. <Redacted B4> water used in the dilution of the firm's cleaning agents, <Redacted B4> and <Redacted B4> are not sterile. These products are used in the ISO 5 rooms and hoods.

I

4 E. Spray bottles used to store <Redacted B4> and <Redacted B4> are non-sterile. These bottles are maintained in the ISO 5 and ISO 7 Clean Rooms during production.

I

Observation 6

There are no written procedures for production and process controls designed to assure that the drug products have the identity, strength, quality, and purity they purports or are represented to possess.

AM ENDMENT 1

Specifically,

A. The firm's <Redacted B4> validation performed 07/2015 to 07/2016 is deficient. The Phase 1&2 summary report memo dated 09/22/15 lacks supporting data. There is not an assessment and final report for Phase 3. The Quality Unit failed to review and approve the validation report for Phase 1&2. The non-sterile water produced by the <Redacted B4> system is used for the production of sterile drug products and for the dilution of cleaning agents used in the ISO 5 areas.

'.(6)(4) B. There is no validation for the foms water system. <Redacted B4> water is non-sterile and is used for the dilution of cleaning agents used in the ISO 5 areas and production of non-sterile drug products.

Observation 7

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

Your firm did not continuously monitor differential pressures in the ISO 5 Clean Room <Redacted B4> from 07/01/18 to 07/25/19.

Your firm did not continuously monitor non-viable particles in ISO 5 Clean Room <Redacted B4> from 10/25/18 to 07/25/19; <Redacted B4> ISO 7 Clean Room <Redacted B4> from 07/01/18 to 07/25/19; and ISO 7 Clean Room <Redacted B4> from 07/01/18 to 08/01/19. In addition, your firm does not continuously monitor non-viable particles in ISO 5 laminar airflow hoods and BSC hoods.

Your fom lacks scientific rationale for the limited environmental surface monitoring during compounding operations.

Observation 8

Aseptic processing areas are deficient regarding systems for maintaining any equipment used to control the aseptic conditions.

AM ENDMENT 1

Observation 9

Routine calibration of automatic, mechanical and electronic equipment is not performed according to a written program designed to assure proper performance.

Specifically,

ISO 5 LAFW and BSC hoods are not always recertified when moved from one room to another. Examples include, but are not limited to the following:

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19. Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . after movement Clean Room <Redacted B4> Clean Room <Redacted B4> in 07/12/19.

Hood 568-not recertified . ...

Read the full 483 (PDF on fda.gov)

Observation 10

Procedures describing the handling of all written and oral complaints regarding a drug product are not followed.

Specifically, your firm's Quality Unit failed to perform and complete quality complaint investigations. Investigations often lacked the following: an investigation, Quality Unit approval, a root cause, an assessment of related complaints, an assessment of the lot affected, and corrective and preventative actions. Examples from 2018 and 2019 include, but are not limited the following:

CAR#740-MF

CAR#454

CAR#358

CAR#419

AMENDMENT 1

CAR #263 and #264

CAR-00-687

CAR-00-681

CAR-00-666

CAR-00-547

CAR-00-473

AE-19-001

Observation 11

Drug products do not bear an expiration date determined by appropriate stability data to assure they meet applicable standards of identity, strength, quality and purity at the time of use.

Specifically, your firm has failed to perform stability testing on sterile drug formulas and non-sterile drug formulas. Examples include, but are not limited to the following sterile and non-sterile drug products:

CARNITINE (L) 170MG/ML INJ 27 ML, COMPOUNDED, Lot 05152019@9

METHIONINE/INOSITOL/CHOLINE, COMPOUNDED 25/50/50MG/ML INJ 30 ML, Lot 04252019@6

ALPHA LIPOIC ACID (PF) COMPOUNDED 25 MG/ML INJ 30 ML, Lot 05292019@7

ASCORBIC ACID (TAPIOCA SOURCE) (PF) COMPOUNDED 500 MG/ML INJ 50 ML, Lot 06182019@4

KETAMINE IN 0.9% SODIUM CHLORIDE (PF) 5 ML FILL IN 6 ML SYRINGE, COMPOUNDED 10 MG/ML(!%) SYRINGE 5ML, Lot 03212019@20

DEXAMETHASONE SODIUM PHOSPHATE, COMPOUNDED 24 MG/ML INJ 5 ML, Lot 05222019@8

FENTANYL CITRATE IN 0.9% SODIUM CHLORIDE (PF) COMPOUNDED, 100 ML FILL IN 150 ML IV BAG 25 MCG/ML IV -I00ML, Lot 06142019@22

NEOSTIGMINE METHYLSULF ATE (PF), 5 ML FILL IN 6 ML SYRINGE, COMPOUNDED 1 MG/ML SYRINGE 5ML, Lot 06122019@18

AM ENDMENT 1 ...

Read the full 483 (PDF on fda.gov)

Observation 12

Testing and release of drug product for distribution do not include appropriate laboratory determination of satisfactory conformance to the final specifications and identity and strength of each active ingredient prior to release.

Specifically, your firm does not perform potency testing prior to release for any non-sterile drug formulations. Examples include, but are not limited to the following non-sterile drug products:

BENZO/LIDO/TETRACAINE TOPICAL, COMPOUNDED, 20%-8%-4% CREAM, Lot 07312019@33

HUMAN CHORIONIC GONADOTROPIN ODT, COMPOU%-NDED 500 UNITS TABLET, Lot02202019@28

HUMAN CHORIONIC GONADOTROPIN ODT, COMPOUNDED 500 UNITS/TABLET 500 UNITS ODT, Lot 05172019@22

LIDOCAINE/TETRACAINE, COMPOUNDED 20%/7% OINTMENT, Lot 06242019@41

Observation 13

Each lot of components is not withheld from use until the lot has been sampled, tested, examined, and released by the quality control unit.

Specifically, non-sterile <Redacted B4> produced by your firm is used in the production of non-sterile drug products. The system used in the production of the <Redacted B4> water is not validated and the LJ water is not tested to USP prior to use. Examples include, but are not limited to the following:

AM ENDMENT 1

MANNA WAY ANTIGEN, COMPOUNDED 100 MCG/ML lML TOP SOLN, Lot 04152019@30

STAINZYME, COMPOUNDED 1 ML FILL IN 3 ML DROPTAINER 100 MCG/ML TOPICAL SOLU, Lot 04152019@31

PROTEASE PPA 1897, COMPOUNDED 1 ML FILL IN 3 ML DROPTAINER 100 MCG/ML TOPICAL SOLU, Lot 04152019@54

CAREZYME, COMPOUNDED 1 ML FILL IN 3 ML DROPTAINER 100 MCG/ML TOPICAL SOLU, Lot 04152019@33

Observation 14

The container labels of your outsourcing facility's drug products are deficient.

Specifically, information to facilitate adverse event reporting is not included on all container labels. The information required includes:

• • 1-800-FDA-1088 Drug products lacking the required information include, but are not limited to:

www.fda.gov/medwatch

MANNAWAY ANTIGEN, COMPOUNDED 100 MCG/ML lML TOP SOLN, Lot 04152019@30

STAINZYME, COMPOUNDED 1 ML FILL IN 3 ML DROPTAINER 100 MCG/ML TOPICAL SOLU, Lot 04152019@31

PROTEASE PPA 1897, COMPOUNDED 1 ML FILL IN 3 ML DROPTAINER 100 MCG/ML TOPICAL SOLU, Lot 04152019@54

CARE2YME, COMPOUNDED 1 ML FILL IN 3 ML DROPTAINER 100 MCG/ML TOPICAL SOLU, Lot 04152019@33

AM ENDMENT 1

Linked 483s whose text is not shown

State board of pharmacy records

The Florida Board of Pharmacy file dated Nov 15, 2026 lists these licenses under the same name, city and state as this pharmacy. Board file.

LicenseType as the board gives itName on the board recordCityStatus
PH23506PharmacyKRS GLOBAL BIOTECHNOLOGY, INCBOCA RATONClosed
PH28942PharmacyKRS GLOBAL BIOTECHNOLOGY, INC.BOCA RATONClosed

Board actions

As the board words them, newest first. An entry that is a complaint, charge or notice the board filed is a charge, not a final decision; only an order or final action records the outcome.

What this covers: Every enforcement action the Florida Department of Health lists for Board of Pharmacy pharmacy permits, worded as the department gives it. The list includes administrative complaints filed as well as final actions, and links no documents. An administrative complaint is an allegation the department has filed, not a finding. Actions in the data are dated Sep 19, 1980 to Nov 10, 2026.

Nonresident licenses and board actions in other states

These boards list a nonresident license or a board action whose record names this pharmacy’s own name, city and state.

California State Board of Pharmacy, file dated Nov 6, 2026 (California).

Colorado State Board of Pharmacy, file dated Nov 15, 2026 (Colorado).

LicenseType as the board gives itName on the board recordLocationStatus
OSP 5777OSPKRS Global Biotechnology, IncBoca Raton, FLVoluntary Surrender

Illinois Department of Financial and Professional Regulation, file dated Nov 13, 2026 (Illinois).

LicenseType as the board gives itName on the board recordLocationStatus
054016707LICENSED PHARMACYKRS GLOBAL BIOTECHNOLOGYBOCA RATON, FLCLOSED

Connecticut Department of Consumer Protection, file dated Nov 15, 2026 (Connecticut).

LicenseType as the board gives itName on the board recordLocationStatus
PCN.0002093NONRESIDENT PHARMACYKRS GLOBAL BIOTECHNOLOGY (dba GBTR)BOCA RATON, FLINACTIVE

Delaware Division of Professional Regulation, file dated Nov 10, 2026 (Delaware).

LicenseType as the board gives itName on the board recordLocationStatus
A9-0000861Non Resident PharmacyKRS Global Biotechnology, Inc.BOCA RATON, FLClosed
A9-0002490Non Resident PharmacyKRS Global Biotechnology, Inc.BOCA RATON, FLClosed
AA-0000028Outsourcing Facility-PharmacyKRS Global Biotechnology, Inc.BOCA RATON, FLClosed
AA-0000071Outsourcing Facility-PharmacyKRS Global Biotechnology, Inc.BOCA RATON, FLClosed

This page restates FDA’s lists and state board of pharmacy records. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.